Partner with us

Pulmokine is pursuing in-licensing and partnership opportunities related to pulmonary and cardiovascular diseases.

As the pre-clinical and clinical development of our new PAH treatment progresses, Pulmokine is aligning with potential partners and investors to carry the project forward. We have received significant interest from larger pharmaceutical companies that want to compete with drug candidates that are currently in clinical testing but which still do not address the root cause of the disease.